BSE has listed 28,00,000 new equity shares of Venmax Drugs and Pharmaceuticals Ltd. (Scrip Code: 531015, ISIN: INE154G01022) for trading effective Thursday, April 23, 2026. The shares were issued at Rs. 20/- each (face value Rs. 10/- + premium Rs. 10/-) to non-promoters on a preferential basis pursuant to the conversion of warrants, and rank pari-passu with existing equity shares.

Key Points

• 28,00,000 equity shares of Rs. 10/- each issued at a premium of Rs. 10/- (total issue price Rs. 20/-) to non-promoters
• Issued on a preferential basis pursuant to conversion of warrants
• Shares rank pari-passu with existing equity shares of the company
• Distribution numbers: 8782931 to 11582930
• Date of allotment: March 23, 2026
• ISIN: INE154G01022
• All 28,00,000 shares are subject to lock-in until November 15, 2026

Regulatory Changes

No regulatory changes. This is a routine listing notification under BSE’s Listing Operations for newly allotted securities.

Compliance Requirements

• Trading members are informed of the new securities and permitted to trade them from April 23, 2026
• Lock-in restrictions apply to all 28,00,000 shares (Dist. Nos. 8782931 to 11582930) until November 15, 2026; these shares cannot be traded until the lock-in expires

Important Dates

• Date of Allotment: March 23, 2026
• Trading Commencement: April 23, 2026
• Lock-in Expiry: November 15, 2026

Impact Assessment

This is a company-specific listing event for a small-cap pharmaceutical company. The addition of 28,00,000 shares expands the total share capital of Venmax Drugs and Pharmaceuticals Ltd. The lock-in period until November 15, 2026 means these shares will not enter the tradeable float immediately, limiting short-term dilution impact on market price. Broader market impact is negligible.